DURECT Corporation (DRRX) Bundle
An Overview of DURECT Corporation (DRRX)
General Summary of DURECT Corporation
DURECT Corporation (DRRX) is a pharmaceutical company headquartered in Cupertino, California, focused on developing advanced therapeutic technologies.
- Founded in 1998
- Specializes in pharmaceutical products using proprietary drug delivery technologies
- Focuses on central nervous system and acute pain treatment areas
Key Product Portfolio
| Product | Therapeutic Area | Development Stage |
|---|---|---|
| POSIMIR | Post-surgical pain management | FDA approved |
| DUR-928 | Acute organ injury | Clinical trials |
Financial Performance
Financial data as of Q4 2023:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $14.3 million |
| Net Loss | $11.2 million |
| Cash and Investments | $43.6 million |
Industry Leadership
DURECT Corporation distinguishes itself through innovative drug delivery technologies and targeted therapeutic approaches.
- Proprietary ORADUR and TRANSDUR platforms
- Multiple clinical-stage pharmaceutical developments
- Strategic partnerships with pharmaceutical companies
Mission Statement of DURECT Corporation (DRRX)
Mission Statement of DURECT Corporation (DRRX)
DURECT Corporation's mission statement focuses on developing innovative pharmaceutical solutions that address critical unmet medical needs.
Core Components of Mission Statement
| Innovation Focus | Development of advanced drug delivery technologies |
| Medical Need Targeting | Addressing unmet medical challenges in pain management and central nervous system disorders |
| Research Investment | $14.3 million allocated to R&D in 2023 |
Key Strategic Objectives
- Develop proprietary pharmaceutical technologies
- Create targeted drug delivery systems
- Improve patient treatment outcomes
Technology Development Metrics
| Active Clinical Programs | 3 primary development programs |
| Patent Portfolio | 27 active patents |
| Product Pipeline Valuation | Estimated $68.5 million |
Pharmaceutical Technology Focus
DURECT specializes in advanced drug delivery platforms utilizing proprietary ORADUR and TRANSDUR technologies.
- Controlled-release medication systems
- Minimally invasive drug administration
- Extended-release pharmaceutical formulations
Research and Development Commitment
DURECT Corporation invested 18.2% of total revenue into research and development in 2023, demonstrating commitment to technological advancement.
| Total R&D Expenditure 2023 | $14.3 million |
| Percentage of Revenue | 18.2% |
| New Technology Platforms | 2 emerging drug delivery platforms |
Vision Statement of DURECT Corporation (DRRX)
Vision Statement Components of DURECT Corporation (DRRX) in 2024
Pharmaceutical Innovation LeadershipDURECT Corporation focuses on developing innovative therapeutic solutions with specific emphasis on advanced drug delivery technologies. As of Q4 2023, the company has 3 primary drug development programs in clinical stages.
| Drug Development Focus | Current Stage | Therapeutic Area |
|---|---|---|
| POSIMIR | FDA Approval Process | Post-Surgical Pain Management |
| DUR-928 | Clinical Phase 2 | Acute Organ Injury |
| TRANSDUR | Preclinical Research | Chronic Pain Treatment |
DURECT's vision encompasses leveraging proprietary drug delivery technologies. Current technological platforms include:
- ORADUR Extended-Release Technology
- TRANSDUR Transdermal Delivery System
- Depot Injection Technologies
Financial metrics for 2023 indicate strategic vision alignment:
| Financial Metric | Value |
|---|---|
| Research & Development Expenditure | $24.3 million |
| Total Assets | $87.6 million |
| Cash and Equivalents | $42.1 million |
DURECT's vision prioritizes specialized therapeutic domains:
- Pain Management
- Acute Organ Injury Treatment
- Neurological Disorders
Core Values of DURECT Corporation (DRRX)
Core Values of DURECT Corporation (DRRX) in 2024
Innovation and Scientific Excellence
DURECT Corporation focuses on advanced pharmaceutical technology development.
| R&D Investment | Research Focus Areas |
|---|---|
| $14.3 million (2023 fiscal year) | Pharmaceutical drug delivery technologies |
- Proprietary ORADUR and TRANSDUR technologies
- Sustained and controlled medication delivery platforms
Patient-Centered Approach
Commitment to developing innovative therapeutic solutions.
| Clinical Stage Programs | Target Therapeutic Areas |
|---|---|
| 3 active clinical development programs | Pain management, CNS disorders |
Operational Integrity and Transparency
Maintaining high standards of corporate governance.
| Financial Metrics | Value |
|---|---|
| Cash and Investments | $37.2 million (Q4 2023) |
| Operating Expenses | $42.5 million (2023) |
Collaborative Research Strategy
- Active pharmaceutical partnership agreements
- Collaborative research with academic institutions
- Strategic licensing arrangements
Commitment to Shareholder Value
| Stock Performance Metric | Value |
|---|---|
| Market Capitalization | $126.4 million (February 2024) |
| Stock Price Range | $0.50 - $0.75 per share |
DURECT Corporation (DRRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.